Both stacks exploit the same GHRH+GHRP synergy, but differ in the GHRH component: CJC-1295 + Ipamorelin : CJC-1295 (with DAC) has a prolonged half-life (~8 days) due to its binding to albumin
(2007) investigated tesamorelin in a randomized clinical trial and demonstrated its ability to stimulate endogenous GH secretion and modulate visceral adipose tissue parameters, establishing the clinical profile of this blend component [1]
Arguments Against the FDAs Decision: Potential Health Benefits: Advocates emphasize the reported benefits observed in animal studies and limited human use, arguing these should be weighed alongside regulatory concerns
An interesting point would be the use of the same dose range in BPC 157 studies [1,2,3,4,5,6,7,8,9,10,11]
When you switch to a different strength, you need to change the amount you give